Vaxil Bio Ltd. (“
Vaxil” or the
“
Company”) (TSXV:VXL) and Green Data Center Real
Estate Inc., a corporation existing under the laws of British
Columbia (“
Green Data”) are pleased to announce
that they have entered into a non-binding letter of intent dated
May 25, 2024 (the “
LOI”), pursuant to which Vaxil
and Green Data intend to complete a business combination or other
similarly structured transaction which will constitute a reverse
take-over of Vaxil (the “
Transaction”). It is
intended that the Transaction will be an arm’s length “Reverse
Takeover” for Vaxil as that term is defined in Policy 5.2 of the
Corporate Finance Manual of the TSX Venture Exchange (the
“
TSXV”).
The LOI is to be superseded by a business
combination agreement (the “Definitive Agreement”)
to be signed on or prior to June 28, 2024, or such later date as
may be mutually agreed upon by the parties in writing. The
Transaction is subject to requisite regulatory approval, including
the approval of the TSXV, and standard closing conditions,
including the approval of the directors of each of Vaxil and Green
Data of the Definitive Agreement, completion of due diligence
investigations to the satisfaction of each of Vaxil and Green Data,
and the conditions described below. The legal structure for the
Transaction will be confirmed after the parties have considered all
applicable tax, securities law and accounting efficiencies.
Vaxil is at arm's length to Green Data, and no
director, officer or insider of Vaxil or Green Data beneficially
owns, or controls or directs, directly or indirectly, any
securities of the other party. Therefore, the Transaction is
expected to be an Arm's Length Transaction as defined under TSXV
Policy 1.1 - Interpretation and will not be considered a “related
party transaction” for the purpose of Multilateral Instrument
61-101 Protection of Minority Security Holders in Special
Transactions.
About Vaxil Bio Ltd.
Vaxil is incorporated under the provisions of
the Business Corporations Act (Ontario) with its registered and
head office in Toronto, Ontario. Vaxil is a “reporting issuer” in
the provinces of Alberta, British Columbia, and Ontario.
Vaxil will hold a meeting of its shareholders
(the “Vaxil Shareholders’ Meeting”), as soon as
reasonably practicable, to vote on the Transaction and the
Divestment (as defined below) and such other matters,
including:
- a change of name of the Company to
such name as is directed by Green Data and acceptable to applicable
regulatory authorities effective upon closing of the Transaction
(the “Closing”);
- the Consolidation (as defined
below);
- a new equity incentive plan to be
effective upon Closing;
- the election of a slate of
directors appointed by Green Data, which elections will be
effective upon Closing;
- the Transaction; and
- the Divestment (as defined
below).
In addition to the Transaction, it is expected
that prior to the Closing of the Transaction Vaxil will divest all
existing assets except cash to unrelated third parties (the
“Divestment”), which may require shareholder
approval and is subject to approval of the TSXV.
Trading in the common shares of Vaxil (each a
“Vaxil Share”) has been halted in accordance with
the policies of the TSXV and will remain halted until such time as
all required documentation in connection with the Transaction has
been filed with and accepted by, and permission to resume trading
has been obtained from, the TSXV. There can be no assurance that
trading of Vaxil Shares will resume prior to the completion of the
Transaction.
About Green Data Real Estate
Inc.
Green Data’s mission is to sustainably power the
digital world. Green Data develops and plans to construct renewable
energy generation, storage assets and hyperscale datacenters. These
assets are in high demand given increasing digital data creation
and utilization and the exponential pace of Artificial Intelligence
demand and deployment. The International Energy Agency
(IEA) estimates that data center electricity usage may double by
2026. The last 40 years of data center deployment will be
compressed into the next two years - Green Data is positioned to
supply this demand.
Green Data creates value through:
-
Renewable Generation: Solar and wind power
generation produces long term revenue from selling power to the
grid and offers low-cost renewable energy for data center use.
- Battery
Energy Storage Systems (BESS): Green Data is developing a
portfolio of BESS projects that will produce revenue from energy
arbitrage and grid services. BESS projects buy low priced energy
during off peak, low demand hours and sell for a profit during peak
priced hours.
- Data
Centers: Green Data develops powered-land, powered-shells
or fully operational wholesale data centers.
Green Data seeks to pair energy generation,
storage and data centers presenting a major competitive advantage
which results in higher arbitrage for energy storage and lower cost
of power for data centers.
Green Data plans to make use of the Inflation
Reduction Act Investment Tax Credit (ITC) in America which provides
up to 30% of CAPEX plus an additional 10% for each: domestic US
content, historical hydrocarbon development area (an energy
community) or low-income communities.
Green Data has assembled a pipeline of BESS and
data center development projects in strategic locations where
project fundamentals and high demand provides near term development
potential. Typical development projects focus on the selection of
prime sites that offer the necessary regulatory environment,
infrastructure, connectivity and energy resource availability and
redundancy for operation. Green Data is currently developing near
term, economically attractive projects and will provide additional
information in advance of the Vaxil Shareholders’ Meeting.
Additional information about Green Data may be
found on its website: www.greendatacenters.com
Concurrent Financing
In connection with the Transaction, Green Data
intends to complete a private placement for gross proceeds of a
minimum of C$2,000,000, through the issuance of securities of Green
Data at a price per security, on a post Share Split (as defined
below) basis, of C$1.50 (the “Concurrent Financing
Price”) or such other price as determined by Green Data
and its advisors in the context of the market (the
“Concurrent Financing”).
The proceeds of the Concurrent Financing will be
used for general corporate and working capital purposes and to fund
development of Green Data’s project pipeline.
Selected Financial Information of Green
Data
The following selected consolidated financial
information of Green Data has been supplied to Vaxil by Green Data
for purposes of inclusion herein in accordance with TSXV
requirements:
|
Year ended December 31, 2023 |
Year ended December 31, 2022 |
(unaudited) |
(unaudited) |
(in US$) |
(in US$) |
Income Statement |
|
|
Revenue |
- |
- |
Total Expenses |
1,302,970 |
669,968 |
Net Income (Loss) |
(1,302,970) |
(669,968) |
Balance Sheet |
Current Assets |
270,943 |
32,108 |
Total Assets |
312,024 |
73,189 |
Current Liabilities |
1,716,417 |
1,314,628 |
Total Liabilities |
1,716,417 |
1,314,628 |
Shareholders' Equity (Deficiency) |
(1,904,393) |
(1,741,439) |
|
Conditions to Transaction
Prior to completion of the Transaction (and as
conditions of Closing):
- Green Data and
Vaxil must complete mutually satisfactory due diligence
investigations;
- the parties
will prepare a management information circular or filing statement
in accordance with the rules of the TSXV, outlining the terms of
the Transaction;
- Vaxil and Green
Data will enter into a Definitive Agreement in respect to the
Transaction on or prior to June 28, 2024;
- Vaxil and Green
Data will obtain the requisite board and, as applicable,
shareholder approvals for the Transaction and any ancillary matters
contemplated in the Definitive Agreement;
- all requisite
regulatory approvals relating to the Transaction, including,
without limitation, the TSXV, will have been obtained; and
- Green Data will
close the Concurrent Financing for gross proceeds of not less than
C$2,000,000 and have a minimum of cash and cash equivalents of
C$1,000,000 at the date of Closing of the Transaction.
The Proposed Transaction
Pre-Closing Capitalization of Vaxil
As of the date hereof, Vaxil has issued and
outstanding 136,978,973 Vaxil Shares and securities exercisable or
exchangeable for, or convertible into, or other rights to acquire,
an aggregate of 13,109,440 Vaxil Shares at various exercise prices
per Vaxil Share. The Vaxil Shares are currently listed on the TSXV
under the symbol “VXL”.
Consolidation of Vaxil
As a condition to Closing the Transaction
immediately prior to Closing, and subject to Vaxil shareholder
approval, Vaxil will undertake a share consolidation (the
“Consolidation”) of approximately 107:1 based on
the following formula: (A/B) * C where:
A |
|
= |
|
Number of issued and outstanding Vaxil Shares immediately prior to
the Consolidation. |
|
|
|
|
|
B |
|
= |
|
Vaxil’s working capital balance
immediately prior to the Transaction, plus the amount owed pursuant
to the Loan (as defined herein), plus C$1,000,000. |
|
|
|
|
|
C |
|
= |
|
C$1.50. |
|
|
|
|
|
Pre-Closing Capitalization of Green Data
Green Data is incorporated under the Business
Corporations Act (British Columbia). As of the date hereof, there
are 1,888,714 common shares in the capital of Green Data (the
“Green Data Shares”) issued and outstanding and
47,524 Green Data Share purchase warrants, 326,411 stock options of
Green Data outstanding. In addition, there are Performance Share
Units (“PSU”) representing 2% of Green Data’s
outstanding common shares at such time each PSU milestone is met in
the future.
Green Data and Vaxil have agreed to pay
1000398274 Ontario Inc. (the “Finder”), an arm’s
length party, a finder’s fee of C$200,000 plus applicable tax,
payable in Green Data Shares immediately prior to the Closing of
the Transaction at a deemed price per Green Data Share equal to the
Concurrent Financing pricing, which would be immediately issued and
exchanged for Vaxil Shares upon the successful Closing of the
Transaction.
Share Split of Green Data
Prior to Closing of the Transaction, Green Data
will undertake a share split (the “Share Split”)
of the Green Data Shares, whereby each 1 pre-split Green Data Share
shall equal approximately 13.7 post-split Green Data Shares.
Terms of the Transaction
It is currently anticipated that Vaxil will
acquire Green Data by way of a three-corner amalgamation, share
exchange, plan of arrangement or other similar form of transaction
as agreed by the parties to ultimately form the resulting issuer
(the “Resulting Issuer”). The final structure of
the Transaction is subject to the receipt of tax, corporate and
securities law advice for both Vaxil and Green Data. Upon
completion of the Transaction, the Resulting Issuer will carry on
the business of Green Data.
Assuming Green Data consummates the Concurrent
Financing for aggregate gross proceeds of C$2,000,000, there will
approximately 28,630,996 common shares in the capital of the
Resulting Issuer (the “Resulting Issuer Shares”)
outstanding following completion of the Transaction. It is expected
that the former shareholders of Green Data will hold approximately
90.3% (on a non-diluted basis) of the Resulting Issuer Shares
(25,866,991 shares) , the former shareholders of Vaxil will hold
approximately 4.5% of the Resulting Issuer Shares (1,280,002
shares), and the investors in the Concurrent Financing will hold
approximately 4.7% of the Resulting Issuer Shares (1,333,336
shares). The Finder will hold approximately 0.5% of the Resulting
Issuer Shares (150,667 shares).
It is expected that the Resulting Issuer will be
classified as a Tier 2 Industrial Technology and Life Sciences
Issuer.
In connection with the Transaction, within 20
days of signing of the LOI, Vaxil will provide Green Data with a
loan facility in an amount of C$250,000 (the
“Loan”), subject to TSXV approval. The Loan will
be secured over the assets of Green Data, including any of the
subsidiaries of Green Data, as well as a pledge of shares of the
subsidiary of Green Data. Interest on the Loan shall accrue on any
outstanding amount at the rate of 12% per annum, payable upon
maturity.
Insiders, Officers and Board of
Directors of the Resulting Issuer
Upon completion of the Transaction, it is
anticipated that the board of directors of the Resulting Issuer
shall consist of 5 directors, a majority of whom shall be nominated
by Green Data. The nominees of Green Data are expected to consist
of Jason Bak, Simon Lee, Mark Goodman and Gadi Levin, with the
remaining board nominees to be determined prior to Closing. The
parties expect Jason Bak to act as CEO.
Following completion of the Transaction, it is
anticipated that Jason Bak will exercise control or direction over
28.5% of the issued and outstanding Resulting Issuer Shares.
The following sets outs the names and bios of
the proposed directors of the Resulting Issuer:
Jason Bak, CEO and Director
Applied Physicist; Founded, publicly listed and
served 17 years as a CEO and Chairman of Finavera Renewables and
Solar Alliance. Led grassroots development of over $1 billion wind
projects (360 MW) all sold to utilities or IPPs and currently
operational. Arranged over C$65 million of public and private
equity and $800M in debt for renewable and infrastructure
development. Led acquisition and operation of three solar companies
in America that resulted in 14,000 installations of residential and
commercial solar. Developed new renewable energy tech and
legislation in wave energy & biofuels. Testified before
Congressional and Senate Committees.
Simon Lee, Director
Simon has over 25 years of experience investing
in and building private market growth businesses with a deep focus
on information technology, data communications, and energy
companies in the US, Western Europe, Asia and the MENA region. He
has been in partnerships that managed, in aggregate, over $8.7
billion, including as General Partner of Sapience Capital Partners,
Infotech Venture Partners and Baker Capital. Simon has been
involved with notable industry leading companies, such as Interxion
(INXN/DLR), Equinix (EQIX), Centeris, Akamai Technologies (AKAM),
Sockeye Networks (INAP), RiverOne (JDAS), EM4 (GHH.L), Totality
(VZ), Perseus (GTT), Turin Networks (Dell), IKIN, Netrolix, and
Fiber Sense. Simon is a graduate of the University of Texas at
Austin and the Harvard Business School.
Mark E. Goodman, Director
Mr. Goodman has over 25 years public and mining
company experience. Most recently he was President of Dundee
Corporation, a TSX listed public mining merchant bank, until
December 2018. He has served on several public company boards and
executive positions of both public and private companies.
Gadi Levin, Director
Mr. Levin is the chairman and CEO of Vaxil Bio
and has also served as Chief Financial Officer and Director of
Vaxil Bio Ltd since March 1, 2016. In addition, Mr. Levin is a
director of EV Nickel Inc. and Eco (Atlantic) Oil and Gas Ltd. Mr.
Levin has over 20 years of experience working with public U.S.,
Canadian and multi-jurisdictional public companies, primarily in
the CFO function. Mr. Levin began his CPA career at the accounting
firm Arthur Andersen, where he worked for nine years, specializing
in U.S. listed companies involved in initial public offerings. Mr.
Levin has a Bachelor of Commerce degree in Accounting and
Information Systems from the University of Cape Town, South Africa,
and a post graduate diploma in Accounting from the University of
South Africa. He received his Chartered Accountant designation in
South Africa and has an MBA from Bar Ilan University in Israel.
The parties have not yet determined who the CFO
or Corporate Secretary of the Resulting Issuer will be. This will
be announced in a subsequent news release once determined.
Sponsorship
The Transaction may require sponsorship under
the policies of the TSXV unless an exemption from sponsorship is
granted. Vaxil intends to apply for an exemption from sponsorship
requirements of the TSXV in connection with the Transaction. There
can be no assurance that such exemption will ultimately be
granted.
Advisors
5X Capital Management is acting as financial
advisor to Green Data.
Further Information
All information contained in this news release
with respect to Vaxil and Green Data was supplied by the parties
respectively, for inclusion herein, and each party and its
directors and officers have relied on the other party for any
information concerning the other party.
The securities to be issued in
connection with the Transaction have not been and will not be
registered under the United States Securities Act of 1933, as
amended (the “U.S. Securities Act”) or any state securities laws
and may not be offered or sold within the United States or to U.S.
Persons (as defined in Regulation S promulgated under the U.S.
Securities Act) unless registered under the U.S. Securities Act and
applicable state securities laws or an exemption from such
registration is available. This press release shall not constitute
an offer to sell or the solicitation of an offer to buy nor shall
there be any sale of the securities in any jurisdiction in which
such offer, solicitation or sale would be unlawful.
Completion of the Transaction is subject to a
number of conditions, including but not limited to, TSXV acceptance
and, if applicable, pursuant to the requirements of the TSXV,
disinterested shareholder approval. Where applicable, the
Transaction cannot close until the required shareholder approval is
obtained. There can be no assurance that the transaction will be
completed as proposed or at all.
Investors are cautioned that, except as
disclosed in the management information circular or filing
statement to be prepared in connection with the Transaction, any
information released or received with respect to the transaction
may not be accurate or complete and should not be relied upon.
Trading in the securities of a capital pool company should be
considered highly speculative.
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS
REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE
POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR
THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Cautionary Statements Regarding Forward
Looking Information
This news release contains “forward-looking
information” within the meaning of applicable securities laws
relating to the proposal to complete the Transaction, the
Divestment and associated transactions. Any such forward-looking
statements may be identified by words such as “expects”,
“anticipates”, “believes”, “projects”, “plans” and similar
expressions. Readers are cautioned not to place undue reliance on
forward-looking statements. Statements about, among other things,
the completion and expected terms of the Transaction and
Divestment, the number of securities of Vaxil that may be issued in
connection with the Transaction, the expected ownership ratio of
the Resulting Issuer post-closing, the completion of the Concurrent
Financing, obtaining the requisite shareholder approval, Green
Data’s strategic plans and the parties’ ability to satisfy closing
conditions and receive necessary approvals, are all forward-looking
information. These statements should not be read as guarantees of
future performance or results. Such statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements to be materially
different from those implied by such statements. Although such
statements are based on management’s reasonable assumptions, there
can be no assurance that the Transaction (including the name change
and Consolidation), the Divestment or the Concurrent Financing will
occur or that, if the Transaction, the Divestment or the Concurrent
Financing do occur, they will be completed on the terms described
above. Vaxil and Green Data assume no responsibility to update or
revise forward-looking information to reflect new events or
circumstances unless required by applicable law.
For more information, please
contact:
Vaxil Bio Ltd. |
Green Data Center Real Estate Inc. |
Gadi Levin, CEO info@vaxil-bio.com +16475585564 |
Jason Bak, CEOjbak@greendatacenters.com |
Vaxil Bio (TSXV:VXL)
Historical Stock Chart
From Nov 2024 to Dec 2024
Vaxil Bio (TSXV:VXL)
Historical Stock Chart
From Dec 2023 to Dec 2024